Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2002-06-22
2008-08-12
Smith, Carolyn (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C702S021000, C435S007230, C436S064000, C703S011000
Reexamination Certificate
active
07412333
ABSTRACT:
A method for treating a patient with cancer includes the steps of obtaining cells from a cancerous tumor in the patient. Then there is the step of performing multiple correlated measurements on each cell to obtain cell data for each cell regarding each cell's place in a genetic evolutionary pathway that had occurred in the tumor. Next there is the step of determining from the cell data a likelihood of recurrence of the cancer by minimizing false negatives. A method for treating a patient with cancer. The method includes the steps of obtaining cells from a cancerous tumor in the patient. Then there is the step of obtaining cell data for each cell regarding each cell's place in a genetic evolutionary pathway that had occurred in the tumor. Next there is the step of recognizing distinctive false negative patterns from the cell data. Then there is the step of correlating the false negative patterns to aberrations in mitogenic signaling to determine a likelihood of recurrence of the cancer in the patient. An apparatus for treating a patient with cancer.
REFERENCES:
patent: 5989811 (1999-11-01), Veltri et al.
Stanley E. Shackney et al., “Origins and Clinical Implications of Aneuploidy in Early Bladder Cancer,”Cytometry (Communications in Clinical Cytometry), Wiley-Liss, Inc., No. 22, p. 307-316, (May 1, 1995).
Stanley E. Shackney et al., “The Accumulation of Multiple Genetic Abnormalities in Individual Tumor Cells in Human Breast Cancers: Clinical Prognostic Implications,” The Cancer Journal, Scientific American, Inc., vol. 2 (No. 2), p. 105-114, (Mar. 1, 1996).
Stanley E. Shackney et al., “Aneuploidy in Breast Cancer: A Fluorescence In Situ Hybridization Study,” Cytometry (Communications in Clinical Cytometry), Wiley-Liss, Inc., No. 22, p. 282-291, (Mar. 7, 1995).
Charles A. Smith et al., “Correlations Among p53, Her-2
eu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas,” Clinical Cancer Research, p. 112-126, (Jan. 1, 2000).
Stanley E. Shackney et al., “Intracellular Coexpression of Epidermal Growth Factor Receptor, Her-2
eu, and p21 ras in Human Breast Cancers: Evidence for the Existence of Distinctive Patterns of Genetic Evolution That Are Common to Tumors from Different Patients,” Clinical Cancer Research, p. 913-928, (Apr. 1, 1998).
Stanley E. Shackney et al., “Common Patterns of Genetic Evolution in Human Solid Tumors,” Cytometry, Wiley-Liss, Inc., p. 1-27, (May 11, 1997).
Stanley E. Shackney et al., “Genetic Evolutionary Staging of Early Non-Small Cell Lung Cancer: The P53<HER-2/NEU>RAS Sequence,” The Journal of Thoracic and Cardiovascular Surgery, vol. 118 (No. 2), p. 259-269, (Aug. 1, 1999).
Laura E. Janocko et al., “Distinctive Patterns of Her-2/Neu, c-myc, and Cyclin D1 Gene Amplification by Fluorescence In Situ Hybridization in Primary Human Breast Cancers,” Cytometry (Communications in Clinical Cytometry), Wiley-Liss, Inc., p. 136-149, (2001).
Stanley E. Shackney et al., “Intracellular Patterns of Her-2
eu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease-Free Survival,” Clinical Cancer Research, p. 3042-3052, (May 1, 2004).
Stanley E. Shackney et al., “Molecular Evolutionary Patterns in Breast Cancer,” Advances in Anatomic Pathology, Lippincott Williams & Wilkins (USA), vol. 10 (No. 5), p. 278-290, (Sep. 2003).
Allegheny-Singer Research Institute
Schwartz Ansel M.
Smith Carolyn
LandOfFree
Method for prognostic factor analysis regarding cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for prognostic factor analysis regarding cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for prognostic factor analysis regarding cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006021